We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
- Authors
Liu, Yuhong; Dai, Xiaoyong; Jiang, Shengwei; Qahar, Mulan; Feng, Chunyan; Guo, Dongdong; Wang, Lijun; Ma, Shaohua; Huang, Laiqiang
- Abstract
Acquired drug resistance decreases the efficacy of gefitinib after approximately 1 year of treatment in non-small-cell lung cancer (NSCLC). Autophagy is a process that could lead to cell death when it is prolonged. Thus, we investigated a drug combination therapy of gefitinib with rapamycin—a cell autophagy activator—in gefitinib-resistant NSCLC cell line H1975 to improve the therapeutic efficacy of gefitinib in advanced NSCLC cells through acute cell autophagy induction. Cell viability and tumor formation assays indicated that rapamycin is strongly synergistic with gefitinib inhibition, both in vitro and in vivo. Mechanistic studies demonstrated that EGFR expression and cell autophagy decreased under gefitinib treatment and were restored after the drug combination therapy, indicating a potential cell autophagy–EGFR positive feedback regulation. To further optimize the delivery efficiency of the combinational agents, we constructed an anti-EGFR aptamer-functionalized nanoparticle (NP-Apt) carrier system. The microscopic observation and cell proliferation assays suggested that NP-Apt achieved remarkably targeted delivery and cytotoxicity in the cancer cells. Taken together, our results suggest that combining rapamycin and gefitinib can be an efficacious therapy to overcome gefitinib resistance in NSCLC, and targeted delivery of the drugs using the aptamer-nanoparticle carrier system further enhances the therapeutic efficacy of gefitinib.
- Subjects
RAPAMYCIN; GEFITINIB; NANOMEDICINE; COMBINATION drug therapy; AUTOPHAGY; NON-small-cell lung carcinoma; KINASE inhibitors; NANOPARTICLES
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 14, p8025
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms23148025